Clinical characteristic or laboratory test abnormalities | Died | Survived | P | ||
---|---|---|---|---|---|
 | data | n | data | n |  |
Medical condition (no) | 6 | 10 | 17 | 58 | 0.076 |
Cigarette index ≥ 400(no) | 2 | 10 | 7 | 58 | 0.611 |
BMI ≥ 24(no) | 9 | 10 | 33 | 58 | 0.045# |
   BMI 24-27.9 | 1 | 10 | 19 | 58 | 0.260 |
   BMI ≥ 28 | 8 | 10 | 14 | 58 | 0.001# |
Median age | 43.5(24-63) | 10 | 41(18-66) | 58 | 0.562 |
Interval from onset of illness to initiation of antiviral therapy, in days | 6(4-10) | 10 | 7(2-15) | 58 | 0.345 |
Lymphocyte count (×109/L) | 0.58(0.02-1.15) | 10 | 0.79(0.31-4.34) | 58 | 0.025** |
LDH(U/L) | 2583(324-4340) | 10 | 775(180-4104) | 57 | 0.003** |
CK(U/L) | 299.5(25-2000) | 10 | 165(20-4188) | 57 | 0.268 |
AST(U/L) | 84(16-225) | 10 | 43(12-339) | 58 | 0.091 |
ALT(U/L) | 54(23-167) | 10 | 41.5(11-204) | 58 | 0.446 |
Alb(g/L) | 27.3(18-33) | 10 | 35(9.6-51) | 58 | 0.003** |
CRP (mg/mL) | 9.515(2.32-27.1) | 8 | 1.49(0.1-29.7) | 57 | 0.001** |
CD4 T cell count (/μL) | 118.5(29-391) | 8 | 470.5(86-1892) | 56 | <0.0005** |
CD8 T cell count (/μL) | 87(23-293) | 8 | 307(44-1113) | 56 | <0.0005** |
CD3 T cell count (/μL) | 219(57-697) | 8 | 784(169-3046) | 56 | <0.0005** |
Lymphocyte count ≤ 0.8×109/L (no) | 9 | 10 | 31 | 58 |  |
Duration of lymphocytopenia | 5.5 (4-19) | 10 | 5 (3-9) | 58 | Â |
Duration of lymphocytopenia > 5 days (no) | 7 | 10 | 4 | 58 | Â |